J&J's clinical Dx business draws private equity bidders; Roche/Ventana rolls out new cancer test;

> A number of major private equity firms have reportedly submitted first-round bids for Johnson & Johnson's ($JNJ) Ortho Clinical Diagnostics unit. Story

> Roche's ($RHHBY) Ventana Medical Systems rolled out a new immunohistochemistry test designed to spot the BRAF V600E mutation in a variety of tumors. Item

> Trovagene ($TROV), a San Diego-based molecular diagnostics company, has launched what it bills as the first urine-based cancer mutation monitoring test. Item

> Insight Genetics inked a global licensing deal with St. Jude Children's Research Hospital for a genetic test that helps predict the success of bone marrow transplants by identifying the ideal bone marrow donor subtype. Item    

> Belgium's MDxHealth won reimbursement for its prostate cancer diagnostic test from two major U.S. insurers. Story

> Switzerland's MolecularHealth, a genetics testing company, hired a Texas-based chief medical officer as it makes plans to open its first U.S. office. Story